Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I5LM
|
||||
| Former ID |
DIB002145
|
||||
| Drug Name |
R-1065
|
||||
| Synonyms |
VR-1065; Ro-60-0332
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Discontinued in Phase 1 | [1] | ||
| Company |
Vernalis Group plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c12c(n(cc2)C[C@@H](N)C)c2c(C1(C)C)ccc(c2)C.C(=O)(/C=C/C<br />(=O)O)O
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017316) | ||||
| REF 2 | Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998 Aug;8(3):161-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.